Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Nikoletta Rovina, Karolina Akinosoglou, Jesper Eugen-Olsen, Salim Hayek, Jochen Reiser, Evangelos J Giamarellos-Bourboulis, Nikoletta Rovina, Karolina Akinosoglou, Jesper Eugen-Olsen, Salim Hayek, Jochen Reiser, Evangelos J Giamarellos-Bourboulis

No abstract available

Keywords: COVID-19; Prognosis; Respiratory failure; suPAR.

Conflict of interest statement

JEO is a co-founder, shareholder, and CSO of ViroGates A/S, Denmark. JEO is an inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark.

JR is a co-founder and shareholder of Trisaq, a biopharmaceutical company that develops drugs that target suPAR.

EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc., and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc., InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis).

All other authors have disclosed that they do not have any conflicts of interest relevant to this submission.

Figures

Fig. 1

suPAR as an early predictor of the development of severe respiratory failure (SRF). a Admission levels of suPAR among Greek patients who eventually developed or not SRF. The p value of comparisons by the Mann-Whitney U test is provided. b Levels of suPAR in patients with COVID-19 and controls. The p value of comparisons by the Mann-Whitney U test is provided. c Time to SRF of Greek patients in relation to the admission levels of suPAR. CI, confidence interval; HR, hazard ratio